Skip to content
Erudio Health
menu
Clinical trial · no report yet · Phase 1/Phase 2

NCT05142696

A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Preliminary discovery

Commentary in our index that names this trial so far

Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.

ChannelFound
X threads2
Bluesky threads1

The trial

ClinicalTrials.gov
Official title
A Phase Ib/II Dose Finding Study Assessing Safety and Efficacy of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC) in Combination With Carboplatin, Etoposide, and Atezolizumab in Induction and With Atezolizumab in Maintenance Phase
Phase
Phase 1/Phase 2
Status
Active, not recruiting
Conditions
Extensive Stage Small Cell Lung Cancer
Interventions
[177Lu]Lu-DOTA-TATE; Atezolizumab; [68Ga]Ga-DOTA-TATE; Carboplatin; Etoposide
Arms
  • Dose Level 1 (DL1) · Experimental
  • Dose Level 2a (DL2a) · Experimental
  • Dose Level 2b (DL2b) · Experimental
  • Dose Level 3a (DL3a) · Experimental
  • Dose Level 3b (DL3b) · Experimental
  • Dose Level 4 (DL4) · Experimental
  • Phase II Experimental arm · Experimental
  • Phase II Control arm · Other
Enrollment
55
Primary outcomes
  • Phase 1b: Frequency of dose limiting toxicities (DLTs), Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs leading to treatment discontinuation
  • Phase ll: Overall survival (OS)
Sponsor
Novartis Pharmaceuticals
Start
Jul 13, 2022
Primary completion
Mar 7, 2028 (estimated)
Results posted
No
Registry record
NCT05142696 · updated Aug 19, 2026